A Review of the Diagnosis, Pharmacologic Treatment, and Economic Aspects of Anxiety Disorders
- PMID: 15014608
- PMCID: PMC181171
- DOI: 10.4088/pcc.v03n0302
A Review of the Diagnosis, Pharmacologic Treatment, and Economic Aspects of Anxiety Disorders
Abstract
As many as 1 in 4 Americans will experience an anxiety disorder at some point in their lives, and many will also suffer the depression, substance abuse, distressing physical signs, and socioeconomic problems that often accompany these disorders when left untreated. Anxiety disorders can be detected using simple screening tools in the physician's office. Early and effective treatment with appropriate medication can significantly reduce the psychic and physical symptoms of anxiety, lowering the overall costs of the disorder to the health care system and society. Many drugs offer safe and effective relief of anxiety symptoms with few side effects or drug-drug interactions, and some offer symptomatic relief within 1 to 2 weeks.
References
-
- DuPont RL, Rice DP, Miller LS, et al. Economic costs of anxiety disorders. Anxiety. 1996;2:167–172. - PubMed
-
- Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50:85–94. - PubMed
-
- Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19. - PubMed
-
- American Psychiatric Association. Anxiety algorithm. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Primary Care Version: DSM-IV-PC. Washington, DC: American Psychiatric Association. 1995 47–63.
-
- Hales RE, Hilty DA, Wise MG. A treatment algorithm for the management of anxiety in primary care practice. J Clin Psychiatry. 1997;58(suppl 3):76–80. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials